Drugs in Dev. Nutrition and Weight Loss
Phase II
Germany 
Lead Product(s) : VK2735
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Viking Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
CordenPharma, Viking Sign GLP-1 Supply Partnership for Peptides & Injectables
Details : CordenPharma provides fill-finish for the drug candidate's subcutaneous formulation and oral solid dosage manufacturing of VK2735. It is being evaluated for obesity.
Product Name : VK2735
Product Type : Peptide
Upfront Cash : Undisclosed
March 11, 2025
Lead Product(s) : VK2735
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Viking Therapeutics
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Boehringer Ingelheim is developing BI 456906, a novel glucagon receptor/GLP-1 receptor dual agonist, for the treatment of people living with overweight or obesity as well as for the treatment people living with of Nonalcoholic Steatohepatatis (NASH).
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
October 05, 2023
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim to Advance Survodutide into Three Global Phase III Studies in Obesity
Details : Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which is investigating for the treatment of weight loss in people living with overweight or obesity.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
August 17, 2023
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Sponsor : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity
Details : The Phase 2 randomized double-blind placebo-controlled dose-finding trial will evaluate GLP-1/glucagon dual agonist, BI 456906, in people with obesity or who are overweight with a BMI 27 kg/m2 or higher without diabetes.
Product Name : BI 456906
Product Type : Peptide
Upfront Cash : Inapplicable
April 13, 2021
Lead Product(s) : Survodutide
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Sponsor : Zealand Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
